|
注册号: Registration number: |
ChiCTR2400081660 |
|
最近更新日期: Date of Last Refreshed on: |
2024-03-07 14:48:39 |
|
注册时间: Date of Registration: |
2024-03-07 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
急性非大中血管闭塞性卒中动脉内尿激酶治疗的多中心、随机、开放标签、盲法终点临床研究 (DISTAL-UK研究) |
|
Public title: |
Efficacy and safety of intra-arterial thrombolysis in acute ischemic stroke patients without large or medium vessel occlusion stroke a multi-center, prospective, randomized, blind-endpoint trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
急性非大中血管闭塞性卒中动脉内尿激酶治疗的多中心、随机、开放标签、盲法终点临床研究 (DISTAL-UK研究) |
|
Scientific title: |
Efficacy and safety of intra-arterial thrombolysis in acute ischemic stroke patients without large or medium vessel occlusion stroke a multi-center, prospective, randomized, blind-endpoint trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
资文杰 |
研究负责人: |
资文杰 |
|
Applicant: |
Wenjie Zi |
Study leader: |
Wenjie Zi |
|
申请注册联系人电话: Applicant telephone: |
+86 185 2303 3816 |
研究负责人电话:
Study leader's |
+86 185 2303 3816 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
ziwenjie1981@163.com |
研究负责人电子邮件: Study leader's E-mail: |
ziwenjie1981@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市沙坪坝区新桥正街183号 |
研究负责人通讯地址: |
重庆市沙坪坝区新桥正街183号 |
|
Applicant address: |
No.183 Xinqiao Main Street, Shapingba District |
Study leader's address: |
No.183 Xinqiao Main Street, Shapingba District |
|
申请注册联系人邮政编码: Applicant postcode: |
400037 |
研究负责人邮政编码: Study leader's postcode: |
400037 |
|
申请人所在单位: |
陆军军医大学第二附属医院 |
||
|
Applicant's institution: |
The Second Affiliated Hospital of the Army Medical University |
||
|
研究负责人所在单位: |
陆军军医大学第二附属医院 |
||
|
Affiliation of the Leader: |
The Second Affiliated Hospital of the Army Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023-研第124-03 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军陆军军医大学第二附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Second Affiliated Hospital of Army Medical University, PLA |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-10-07 00:00:00 | ||
|
伦理委员会联系人: |
胡岚岚 |
||
|
Contact Name of the ethic committee: |
Lanlan Hu |
||
|
伦理委员会联系地址: |
重庆市沙坪坝区新桥正街183号 |
||
|
Contact Address of the ethic committee: |
183 Xinqiao Main Street, Shapingba District, Chongqing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 6877 5422 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
陆军军医大学第二附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Affiliated Hospital of the Army Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市沙坪坝区新桥正街183号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.183 Xinqiao Main Street, Shapingba District |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
陆军军医大学第二附属医院人才建设专项项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
The Special Talent Development Project of the Second Affiliated Hospital of Army Medical University. |
||||||||||||||||||||||
|
研究疾病: |
急性缺血性卒中 |
||||||||||||||||||||||
|
Target disease: |
Acute ischemic stroke |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
探索动脉内尿激酶治疗非大中血管闭塞型卒中患者的疗效性与安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To investigate the efficacy and safety of the intraarterial uroknise for acute ischemic patients without large or medium vessel occlusion. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1)经头颅计算机断层扫描(CT)或核磁共振成像(MRI)证实颅内出血; 2)发病前mRS评分≥2分; 3)DSA造影提示血管穿破、夹层、造影剂外渗等并发症; 4)ASPECTS < 7分; 5)妊娠或哺乳期妇女; 6)对造影剂过敏; 7)收缩压>185mmHg或舒张压>110mmHg,且使用降压药物无法控制; 8)遗传学或获得性出血体质,抗凝因子缺乏;或已使用抗凝药且INR>1.7; 9)血糖<2.8mmol/L(50mg/dl)或>22.2mmol/L(400mg/dl),血小板 < 70*109/L; 10)近1个月有出血史(胃肠道及尿路出血); 11)慢性血液透析及严重肾功能不全(肾小球滤过率<30ml/min或血肌酐>220μmol/L(2.5mg/dl))患者; 12)颅内动脉瘤、动静脉畸形; 13)影像学上具有占位效应的脑肿瘤; 14)任何疾病晚期致预期寿命<6个月; 15)预期不能完成随访; 16)DSA/CTA/MRA检查发现大中血管闭塞; 17)正参加其他临床试验; 18)静脉溶栓患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1)Confirmed intracranial hemorrhage by computed tomography (CT) or magnetic resonance imaging (MRI); 2)Pre-stroke mRS score ≥ 2; 3)Digital subtraction angiography suggests vascular rupture, dissection, extravasation of contrast agent or other complication; 4)Alberta Stroke Program Early CT Score (ASPECTS) < 7; 5)Pregnant or lactating women; 6)Allergy to contrast agent; 7)Systolic blood pressure greater than 180 mmHg or diastolic blood pressure greater than 110 mmHg after aggressive treatment; 8)Genetic or acquired bleeding tendency, deficiency of coagulation factors; or use of anticoagulants with INR>1.7; 9)Blood glucose <2.8mmol/L (50mg/dl) or >22.2mmol/L (400mg/dl), platelets <70*10^9/L; 10)History of bleeding in the past month (intracranial, gastrointestinal and urinary tract bleeding); 11)Chronic hemodialysis and severe renal insufficiency patients (glomerular filtration rate<30ml/min or serum creatinine>220μmol/L(2.5mg/dl)); 12)Intracranial aneurysm, or arteriovenous malformation; 13)Brain tumor(s) with mass effect; 14)Any disease that leads to an expected lifespan of less than 6 months; 15)Unable to complete follow-up as expected; 16)Large- or medium-sized vessel occlusion found on DSA/CTA/MRA examination; 17)Currently participating in other clinical trial; 18)Patients received Intravenous Thrombolysis |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-03-01 00:00:00至 To 2025-04-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-03-07 00:00:00 至 To 2025-03-16 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机化序列将由独立第三方统计师采用SAS9.4生成,并采用中心网络随机APP开展随机化。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The randomization sequence will be generated by an independent third-party statistician using SAS 9.4, and the central network random APP will be used to conduct the randomization. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
开放标签,盲法终点评估 |
|
Blinding: |
Open Label, Blind endpoint |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
相关论文发表5年后公开原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Related papers published five years later, the IPD will be shared |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用病例报告表(CRF) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Use Case Record Form (CRF) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |